Antibody Therapeutics for Life

Press Release

PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS PharmAbcineLogo (PRNewsfoto/PharmAbcine)
  • Written by PharmAbcine
  • Written date 2020-08-20 16:16:13
  • Inquire 3138

PharmAbcine announces the execution of a Material Cooperative Research and Development Agreement (MCRADA) with the NIH to evaluate the efficacy of PMC-403 to treat SCLS







List





Prev PharmAbcine signs a research collaboration agreement with Wuxi Shuangliang Biote...
Next PharmAbcine is presenting at the KSMO 2020